Nicotinamide Mononucleotide Cocrystal Fluidity via Isonicotine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nicotinamide mononucleotide crystals have poor fluidity, leading to larger content/weight differences and inconsistent quality in NMN medicines or healthcare products, affecting their stability and pharmaceutical efficacy.
Innovation Solution
A method for preparing nicotinamide mononucleotide cocrystals by mixing nicotinamide mononucleotide with isonicotine in a 1:1 molar ratio using solution synthesis, with specific solvent systems and temperature control to enhance crystal precipitation and bulk density, resulting in improved fluidity and consistency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If NMN is prepared in crystal form to improve stability, then stability is improved, but fluidity deteriorates leading to larger content/weight difference and inconsistent quality
Solution Approach 1:
The patent creates a cocrystal composite by combining NMN with isonicotine in a 1:1 molar ratio. This composite structure integrates two different molecular components into a single crystalline lattice, where NMN provides stability while isonicotine modifies the crystal packing to improve fluidity. The cocrystal form maintains the stability benefits of crystallization while achieving the desired flow properties for consistent product quality.
Solution Approach 2:
The patent changes the physical and chemical parameters of NMN by forming a cocrystal with isonicotine. This involves altering the molecular arrangement, intermolecular forces, and crystal lattice structure through the introduction of a cocrystal former. The parameter changes in molecular composition and crystal structure simultaneously improve both stability and fluidity properties.
2Reliability
If NMN amorphous powder is used to maintain pharmaceutical activity, then pharmaceutical activity is maintained, but stability deteriorates during storage and transportation
Solution Approach 1:
The patent utilizes phase transition from amorphous to crystalline state by forming a cocrystal. The NMN transitions from an amorphous powder phase (which maintains pharmaceutical activity but lacks stability) to a cocrystal phase (which provides both stability and retained pharmaceutical activity). This controlled phase transition resolves the contradiction between maintaining activity and achieving stability.
3Stability of the object's composition
If conventional crystal forms are used to improve stability, then stability is improved, but content/weight difference increases and quality consistency deteriorates
Solution Approach 1:
The cocrystal composite of NMN and isonicotine creates a more uniform and consistent material with defined stoichiometry (1:1 molar ratio). This composite structure reduces variability in content/weight difference and improves quality consistency during manufacturing, while maintaining the stability benefits of crystallization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method successfully produces nicotinamide mononucleotide-isonicotine cocrystals with higher bulk density and improved fluidity, addressing the issues of content/weight differences and quality inconsistency, while maintaining pharmaceutical activity.
Implementation Method 1
Under the action of hydrogen bonds, π-π stacking, Van der Waals forces or other non-covalent bonds, the two types of cocrystal components are combined in a fixed stoichiometric ratio to generate a new solid form
Implementation Method 2
Under the action of hydrogen bonds, π-π stacking, Van der Waals forces or other non-covalent bonds, the two types of cocrystal components are combined in a fixed stoichiometric ratio to generate a new solid form
Implementation Method 3
Under the action of hydrogen bonds, π-π stacking, Van der Waals forces or other non-covalent bonds, the two types of cocrystal components are combined in a fixed stoichiometric ratio to generate a new solid form
Implementation Method 4
mixing nicotinamide mononucleotide as an active pharmaceutical ingredient with isonicotine as a cocrystal former by adopting solution synthesis and then performing crystal precipitation
Implementation Method 5
mixing nicotinamide mononucleotide as an active pharmaceutical ingredient with isonicotine as a cocrystal former by adopting solution synthesis and then performing crystal precipitation
Data Source
AI summary
The present disclosure provides a method for preparing a nicotinamide mononucleotide cocrystal, and aims to solve the technical problems of larger content/weight difference and inconsistent quality of nicotinamide mononucleotide (NMN) medicines or health care products due to poor fluidity of existing nicotinamide mononucleotide crystals. The method includes the steps of mixing nicotinamide mononucleotide as an active pharmaceutical ingredient with isonicotine as a cocrystal former by adopting solution synthesis and then performing crystal precipitation. The method has the advantages of simple operation and wide application range.